SynthesisBMC cancer2024

Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.

Mingye Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.